PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation (NOTION-3)
Source: View publication →
In patients with severe aortic stenosis and stable coronary artery disease, performing percutaneous coronary intervention prior to or concurrently with TAVI reduced the composite risk of death, myocardial infarction, or urgent revascularization compared to conservative management, though it increased bleeding risk.
Key Findings
Study Design
Study Limitations
Clinical Significance
NOTION-3 demonstrated that fractional flow reserve (FFR)- or angiography-guided PCI for significant coronary artery disease in TAVI patients significantly reduces downstream ischemic events. Although PCI did not improve overall survival and increased bleeding events, the trial establishes an evidence-based foundation for an individualized approach, favoring pre-TAVI PCI to minimize future myocardial infarctions and unplanned revascularizations in patients without a prohibitively high bleeding risk.
Historical Context
Coronary artery disease is present in up to 50% of patients undergoing TAVI. Historically, management paradigms were extrapolated from surgical aortic valve replacement (SAVR), where concomitant CABG is the standard of care. However, in the TAVI era, the necessity and optimal timing of PCI have been controversial. Prior data, such as the ACTIVATION trial, failed to show noninferiority for PCI versus conservative management and highlighted an increased bleeding risk, leaving clinical guidelines without firm recommendations. NOTION-3 was the first adequately powered randomized trial to show a clear ischemic benefit (MACE reduction) for upfront PCI in this population, significantly advancing the debate over balancing ischemic protection against bleeding risk.
Guided Discussion
High-yield insights from every perspective
How does severe aortic stenosis alter the myocardial oxygen supply and demand balance, and why might relieving the stenosis with TAVI change the physiological significance of coexisting stable coronary artery disease?
Key Response
Severe AS causes left ventricular hypertrophy (increasing oxygen demand) and elevated left ventricular end-diastolic pressure (decreasing coronary perfusion gradient and supply). While TAVI immediately relieves the pressure overload, LV mass regresses slowly. Understanding this hemodynamic shift helps students grasp why stable CAD might cause ischemia post-TAVI or why upfront PCI, as done in NOTION-3, might prevent future ischemic events like MI or urgent revascularization.
Given that NOTION-3 showed an increased bleeding risk with the PCI strategy, how do you approach the timing of PCI (staged before vs. concurrent with TAVI) and the choice of antiplatelet regimen in a frail 82-year-old patient to balance ischemic and bleeding risks?
Key Response
Residents must translate trial data into clinical management. While PCI reduced the composite ischemic endpoint, it mandated dual antiplatelet therapy (DAPT), increasing bleeding. Deciding whether to perform PCI concurrently (to reduce access site complications and contrast load) or staged, and selecting an abbreviated DAPT duration, is critical for optimizing outcomes in older, high-bleeding-risk patients.
In patients with severe AS, functional coronary assessments like FFR or iFR can be confounded by microvascular dysfunction and altered resting hemodynamics. How does NOTION-3's methodology for defining significant CAD influence your decision to rely on anatomical vs. physiological lesion assessment in the cath lab prior to TAVI?
Key Response
Fellows must navigate the nuances of the cath lab. Severe AS blunts the hyperemic response due to high LVEDP and microvascular changes, potentially yielding false-negative FFR results. NOTION-3 utilized a pragmatic approach (FFR <= 0.80 or high-grade >=90% stenosis). Fellows must critically evaluate whether physiological testing is robust enough in AS or if anatomical severity should take precedence when planning revascularization.
For years, a conservative 'leave it alone' strategy for bystander CAD in TAVI was often favored to avoid procedural complexity and DAPT in frail elderly populations. Does NOTION-3 definitively shift your default practice to routine PCI, or are there specific anatomical or patient phenotypes where you would intentionally deviate from the trial's intervention arm?
Key Response
Attendings are responsible for overarching clinical strategy. NOTION-3 provides strong RCT data favoring PCI, but real-world application requires nuanced shared decision-making. Attendings must weigh the trial's average benefit against individual patient factors like extreme frailty, heavily calcified tortuous coronaries, or previous life-threatening bleeds, recognizing that 'one size does not fit all' despite positive trial results.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
NOTION-3 utilized a composite primary endpoint of all-cause death, MI, or urgent revascularization. In a predominantly elderly TAVI population with high baseline mortality, how do competing risks of non-cardiovascular death affect the interpretation of time-to-event analyses (e.g., Kaplan-Meier) for the ischemia-driven components of the outcome?
Key Response
Methodologists must consider that in an octogenarian population, high rates of non-cardiovascular mortality act as a competing risk for events like MI or revascularization. Using standard Kaplan-Meier estimates can artificially inflate the cumulative incidence of these softer ischemic endpoints. A PhD-level critique involves assessing whether the authors appropriately utilized cumulative incidence functions (e.g., Fine-Gray models) to account for these competing risks.
Because NOTION-3 involved procedural interventions, blinding of patients and treating physicians was impossible. As a reviewer, how concerned are you that the 'urgent revascularization' component of the primary composite endpoint was driven by ascertainment bias or a lower threshold to intervene in the conservative arm, and how should the manuscript address this threat to validity?
Key Response
A critical peer reviewer must flag the lack of blinding, which heavily biases subjective or decision-driven endpoints like 'urgent revascularization.' Knowing a patient has untreated CAD might prompt a physician to perform an angiogram and revascularize for ambiguous symptoms. The reviewer would demand rigorous, blinded clinical event adjudication and a sensitivity analysis of the hard endpoints (death and MI) alone to ensure the trial's conclusions are robust.
Current ACC/AHA guidelines provide a Class IIa recommendation for PCI in patients with significant CAD undergoing TAVI. Based on the NOTION-3 findings of reduced ischemic events but higher bleeding, should this recommendation be upgraded to Class I, and what specific criteria should define the threshold for mandatory intervention in the updated guidelines?
Key Response
Guideline committees must integrate new RCTs with existing recommendations. NOTION-3 offers Level B-R evidence supporting PCI, potentially justifying an upgrade to a Class I recommendation. However, the committee must carefully construct the recommendation text to define 'significant CAD' (e.g., proximal lesions, specific FFR thresholds) and explicitly advise on mitigating the heightened bleeding risk, ensuring the guideline promotes net clinical benefit.
Clinical Landscape
Noteworthy Related Trials
ISCHEMIA Trial
Tested
Routine invasive strategy (PCI/CABG) + medical therapy
Population
Patients with stable CAD and moderate-to-severe ischemia
Comparator
Optimal medical therapy alone
Endpoint
Composite of CV death, MI, resuscitated cardiac arrest, or hospitalization for UA/HF
POPular TAVI Trial
Tested
Single antiplatelet therapy (Aspirin)
Population
Patients undergoing TAVI without an indication for OAC
Comparator
Dual antiplatelet therapy (Aspirin + Clopidogrel)
Endpoint
All bleeding and non-procedure-related bleeding at 1 year
ACTIVATION Trial
Tested
PCI prior to TAVI
Population
Patients with severe aortic stenosis and significant CAD
Comparator
TAVI alone (conservative CAD management)
Endpoint
Composite of death and rehospitalization at 1 year
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis